Tamoxifen to raloxifene and beyond

Seminars in Oncology

Volumn 28, Issue 3, 2001, Pages 260-273

  O'Regan, Ruth M ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; DROLOXIFENE; EXEMESTANE; FORMESTANE; FULVESTRANT; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; BONE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034979311     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.23492     Document Type: Article

References (119)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
2. Tamoxifen for early breast cancer: An overview of the randomized trials
3. The effects of raloxifene on the risk of breast cancer in postmenopausal women: Results from the more randomized trial. Multiple outcomes of raloxifene evaluation
4. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
5. Tamoxifen and contralateral breast cancer
6. Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early stage breast cancer
7. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer
8. Prolonged follow-up of the Swedish randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer and relationships to hormone receptor and ERB2 levels
9. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
10. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
11. Antitumor activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model
12. Effects of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
13. Pharmacology of tamoxifen in laboratory animals
14. Evaluation of the anitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in DMBA-induced rat mammary carcinoma model
15. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitromethylurea-induced rat mammary carcinoma model
16. Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of radiation-induced mammary tumors in female Sprague Dawley rats
17. Supression of mouse mammary tumorgenesis by long-term tamoxifen therapy
18. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
19. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
20. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after five years of treatment
21. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
22. Interim analysis of the incident breast cancer in the Royal Marsden Hospital tamoxifen randomized prevention trial
23. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
24. Projecting individualized probabilities of developing breast cancer from white women who are being examined annually
25. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women
26. Effects of antiestrogens on bone in castrated and intact female rats
27. Tamoxifen prevents the skeletal effects of ovarian hormone definciency in rats
28. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
29. Tamoxifen, serum lipoproteins and cardiovascular risk
30. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
31. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
32. Tamoxifen decreases lipoprotein(a) in patients with breast cancer
33. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen
34. Systemic therapy of early breast cancer by hormonal, cytotoxic and immune therapy: 133 Randomized trials involving 331,000 recurrances and 24,000 deaths among 75,000 women
35. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen
36. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
37. Coronary heart disease mortality and adjuvant tamoxifen therapy
38. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
39. High-grade endometrial carcinoma in tamoxifen treated breast cancer patients
40. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture
41. Effect of steroidal and non-steroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice
42. Effects of the new antiestrogen keoxifene LY 156758 on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
43. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
44. Raloxifene (LY 139,481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
45. Dual energy x-ray absorbiometry of raloxifene effects on lumbar vertebrae and femora of ovariectomized rats
46. Longitudinal and cross sectional analysis of raloxifene effects on tibiae from ovariectomized rats
47. Raloxifene preserves bone strength and bone mass in ovariectomized rats
48. Effects of raloxifene (LY 139,481 HCL) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women
49. Antiestrogenic properties of keoxifene, trans 4-hydroxytamoxifen and ICI 164,380, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells
50. A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens
51. Phase II evaluation of LY 156758 in metastatic breast cancer
52. Raloxifene HCL, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer
53. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in ∼ 12,000 postmenopausal women
54. Antiestrogens 2: Structure-activity studies in a series of 3 aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydrotyphenyl) benzo[b]thiene-3-yl] [4-[2-(1-piperidinyl) ethoxy-phenyl] methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal estrogenicity
55. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
56. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY 117018) in rats and mice
57. Inhibition of the uterotropic activity of antiestrogens by the short acting antiestrogen LY 117018
58. Differential antiestrogen action on the immature rat uterus: A comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor
59. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor (ER)
60. Apoptosis in toremifene growth inhibition of human breast cancer cells in vivo and in vitro
61. Effect of the antiestrogen toremifene on growth of human mammary carcinoma cell line MCF-7
62. Inhibition of hormone dependent and independent breast cancer growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon α2
63. Antiestrogen action of toremifene on hormone-dependent, independent and heterogeneous breast tumor growth in the athymic mouse
64. Antitumor actions of toremifene in the 7,12 dimethylbenzanthracene (DMBA)-induced rat mammary tumor model
65. A new triphenylethylene compound Fc-1157a II antitumor effects
66. Growth characteristics of human endometrial cancer transplanted in athymic mice and treated with new antiestrogens, toremifene and ICI 182,780
67. Toxicity and early survival results of a prospective, ramdomized adjuvant trial comparing toremifene and tamoxifen in node-positive breast cancer
68. Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antiestrogens
69. Toremifene, a new antiestrogenic treatment of advanced breast cancer Phase II study
70. Low-dose toremifene in the treatment of estrogen receptor-positive advanced breast cancer in postmenopausal women
71. Phase II experience with toremifene in the treatment of ER-positive breast cancer of postmenopausal women
72. Toremifene, a new antiestrogenic compound in the treatment of advanced breast cancer. Phase II study
73. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer - An ongoing phase II multicenter Finnish-Latvian cooperative study
74. Phase II clinical study of toremifene in patients with metastatic breast cancer
75. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
76. Clinical evaluation of NK 22 (toremifene citrate) in advanced or recurrent breast cancer - A comparative study by a double blind method with tamoxifen
77. Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial
78. Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer
79. Antiestrogen action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7f
80. No loss of estrogenic and antiestrogenic activity after demethylation of droloxifene (3-OH tamoxifen)
81. Pharmacologic and biologic properties of droloxifene, a new antiestrogen
82. Preclinical data for droloxifene
83. Antitumor effects of droloxifene, a new antiestrogen drug against 7,12 dimethyl (a) anthracene-induced mammary tumor in rats
84. Investigations of droloxifene and other hormonal manipulations on N-nitro-somethylurea-induced rat mammary tumours
85. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen
86. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss on ovariectomized rats
87. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
88. European early phase II dose finding study of droloxifene in advanced breast cancer
89. Inhibition of growth of human cancer by intermittent exposure to the antiestrogen droloxifene
90. Phase I study of FK 435
91. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer
92. Droloxifene - A new anti-estrogen phase II study in advanced breast cancer
93. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
94. Metabolism of the 4 iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites
95. Idoxifene: Report of a phase I study in patients with metastatic disease
96. Discovery and synthesis of [6-hydroxy-3-[4-(1-piperidinyl)-ethoxy-phenoxy]-2-(4-hydroxyphenyl) benzo[b]thiophene: A novel, highly potent selective estrogen receptor modulator (SERM)
97. LY 353,381.HCL: A highly potent, orally active selective estrogen receptor modulator
98. LY 353,381.HCL: A novel raloxifene analog with improved SERM potency and efficacy in vivo
99. Pharmacodynamics and pharmacokinetics of LY 353381.HCL, a selective estrogen receptor modulator (SERM) in women with refractory, metastatic breast cancer
100. Characteriztion of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro
101. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice
102. Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]an-thracene-induced mammary carcinoma in rats
103. Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice
104. Effects of EM-652.HCL (SCH 57068.HCL), raloxifene and tamoxifen, administered alone or in combination, on rat endometrial epithelial height and vaginal weight
105. A potent specific pure antiestrogen with clinical potential
106. Aniestrogen ICI 164,384 reduces cellular estrogen receptor by increasing its turnover
107. The mechanism of ICI 164, 384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
108. Human breast cancer in athymic nude mice: Cytostatic effects of long-term antiestrogenic activity
109. Comparison of the effects of a pure steroidal aniestrogen with those of tamoxifen in a model of human cancer
110. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
111. Source of estrogen production in postmenopausal women
112. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs and abdomen of women increase with advancing age
113. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
114. Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminiglutethimide in post-menopausal women with advanced breast cancer
115. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
116. Exemestane is superior to megestrol acetate after tamoxifen failure in post-menopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
117. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a does effect and improved efficacy and tolerability compared with megestrol acetate
118. Chemoprevention of breast cancer: The coming of age of antiestrogens
119. Selective oestrogen receptor modulation: Molecular pharmacology for the milenium